The Ad-TK/GCV system is well tolerated for the treatment of liver cancer because no serious side effects were observed in patients receiving up to 2 × 1012 virions, and the tumors remained stable and even developed necrotizing signs in some patients (Sangro et al., 2010). The gene discussed is TKT; the disease is liver cancer.